Objective Oral tyrosine kinase inhibitor has been shown to prolong progression-free survival
(PFS) in epidermal growthfactor receptor (EGFR) mutation positive adenocarcinoma; …

Purpose Patients with advanced non-small cell lung cancer (NSCLC) harboring a sensitive
epidermal growth factor receptor (EGFR) mutation have been shown to exhibit a marked …

Background Increased evidences show that epidermal growth factor receptor (EGFR)-
tyrosine kinase inhibitors such as gefitinib could prolong progression-free survival (PFS) …

PURPOSE Standard first-line therapy for EGFR-mutant advanced non–small-cell lung
cancer (NSCLC) is an epidermal growth factor receptor (EGFR)–directed oral tyrosine …

To explore the optimal treatment strategy for patients who harbor sensitive EGFR mutations,
a head‐to‐head study was performed to compare chemotherapy and gefitinib in …

Aim: Most patients (pts) with EGFR mutation-positive NSCLC respond to 1st-line EGFR
tyrosine kinase inhibitors, but later acquire resistance. The Phase III, double-blind IRESSA …

Background Previously, we demonstrated that treatment with gefitinib combined with
pemetrexed plus carboplatin chemotherapy improved progression-free survival (PFS) …

Background Patients with non-small-cell lung cancer harbouring mutations in the epidermal
growth factor receptor (EGFR) gene respond well to the EGFR-specific tyrosine kinase …

Purpose To determine whether the addition of pemetrexed to gefitinib (P+ G) provides
clinical benefit, compared with gefitinib monotherapy, in patients with advanced …

This study was designed to prospectively evaluate the efficacy and safety of first-line gefitinib
treatment in patients with advanced pulmonary adenocarcinoma harboring epidermal …